Global Ganja Report

In Washington state, glitches in the "seed-to-sale" tracking system nearly paralyzed the cannabis industry statewide last month, costing retailers hundreds of thousands of dollars and forcing temporary lay-offs of employees. Similar headlines have been seen from across the country's legalized states—pointing to a persistent issue.

The US Department of Agriculture is opening an Industrial Hemp Germplasm Repository, in conjunction with upstate New York's Cornell University. The facility is envisioned as a major hub for genetic analysis and research, helping to spur the hemp industry's growth regionally and nationally.

Democratic presidential hopeful Tulsi Gabbard has won support from many activists for her embrace of cannabis legalization (as well as her anti-war rhetoric). Gabbard has been more fearless in her disregard of the cannabis stigma than any of the others in the Democratic field.

Hundreds of cannabis possession charges have been dismissed in Texas in recent weeks because police don't have labs that can differentiate between marijuana and newly legal hemp. The governor, attorney general and politicians are up in arms about it. Other states are updating their test kits to distinguish between CBD and THC in confiscated samples.

An ICE raid in the LA district of Echo Park sparked local outrage, with a longtime resident and pregnant mother of two detained for deportation—despite the fact that the agents apparently had no warrant. Her family is now left struggling—and it all seems based on a cannabis conviction from many years ago.

Paul Krassner, the legendary underground-press publisher, counterculture comedian, and the man credited with naming the Yippies, died July 21 at his home in Desert Hot Springs, Calif. He was 87 years old, and still active in radical press endeavors.

Activists in North Dakota are heartened by the state's recent reduction of cannabis penalties, but insist that (contrary to media reports) it is not true decriminalization. And they are gearing up a new effort to get a legalization initiative approved in next year's elections.

With industry waiting on the FDA to issue regs for CBD products, the agency instead released a statement explaining why it has not yet done so—including fears that the trendy cannabinoid may cause liver damage. But advocates charge that the claim is based on faulty research.